Deletion of the Ste20-like kinase SLK in HER2+ breast cancers activates an alternate Akt-Sox10 pathway

HER2 乳腺癌中 Ste20 样激酶 SLK 的缺失会激活替代的 Akt-Sox10 通路

• 批准号: 389123
• 负责人: Sabourin Luc A
• 金额: $ 62.31万
• 依托单位: Ottawa Hospital Research Institute
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2018
• 资助国家: 加拿大
• 起止时间: 2018-09-01 至 2023-09-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=389123&lang=en
• 关键词: Akt; Her2; Knock Out; Slk; Sox10; Transgenics

HER2 is overexpressed in about 30% of all breast cancer and is associated with a poor prognosis. We have identified a protein termed SLK that is required for cell growth, motility and invasion. We have genetically deleted this protein in a mouse model of

HER2在约30%的乳腺癌中过表达，并且与不良预后相关。我们已经确定了一种蛋白质称为SLK，是所需的细胞生长，运动和入侵。我们已经在一个小鼠模型中基因删除了这种蛋白质，